Health
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen
RAHWAY, N.J. & NUTLEY, N.J., October 18, 2025--KEYTRUDA Plus LENVIMA Demonstrates Durable 5-Year Survival Benefit Vs Chemotherapy for Patients With Advanced Endometrial Carcinoma
About this update from Eisai Co., Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":217,"url":"https://media.zenfs.com/en/business-wire.com/6668846d66178c34e9d9cdea2e0cddf7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/M4cp26jQbJd7iz3qk6vhgA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQzNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/6668846d66178c34e9d9cdea2e0cddf7","width":480,"height":217}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":324,"url":"https://media.zenfs.com/en/business-wire.com/205b721b3df0b1f8afd6006a91cea747"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3IUtEzpDCu.35aq1ElbttQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY0ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/205b721b3df0b1f8afd6006a91cea747","width":480,"height":324}}},{"type":"text","content":"At five years, KEYTRUDA plus LENVIMA showed a 16.7% overall survival (OS) rate for these patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma versus 7.3% for chemotherapy alone in the pivotal Phase 3 KEYNOTE-775/Study 309 trial","length":253,"tagName":"p","attribs":{}},{"type":"text","content":"Five-year OS results in the pMMR subgroup were consistent with the all-comers study population, which demonstrated an OS rate of 19.9% for KEYTRUDA plus LENVIMA versus 7.7% for chemotherapy","length":189,"tagName":"p","attribs":{}},{"type":"text","content":"RAHWAY, N.J. & NUTLEY, N.J., October 18, 2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced long-term follow-up data continued to show durable benefit of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, plus LENVIMA® (lenvatinib), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, compared to chemotherapy for patients with advanced endometrial carcinoma following at least one prior platinum-based regimen in any setting. The findings, based on five years of follow-up from the Phase 3 KEYNOTE-775/Study 309 trial evaluating KEYTRUDA plus LENVIMA versus chemotherapy (treatment of physician’s choice of doxorubicin or paclitaxel), for these patients with advanced endo...